BG60755B2 - Мометазонфуроат монохидрат, метод за получаването му и фармацевтичен състав - Google Patents

Мометазонфуроат монохидрат, метод за получаването му и фармацевтичен състав Download PDF

Info

Publication number
BG60755B2
BG60755B2 BG098564A BG9856494A BG60755B2 BG 60755 B2 BG60755 B2 BG 60755B2 BG 098564 A BG098564 A BG 098564A BG 9856494 A BG9856494 A BG 9856494A BG 60755 B2 BG60755 B2 BG 60755B2
Authority
BG
Bulgaria
Prior art keywords
monohydrate
mometasone furoate
water
furoate
pregnadiene
Prior art date
Application number
BG098564A
Other languages
Bulgarian (bg)
English (en)
Inventor
Pui-Ho Yuen
Charles Eckhart
Teresa Etlinger
Nancy Levine
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG60755(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of BG60755B2 publication Critical patent/BG60755B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BG098564A 1990-09-10 1994-02-24 Мометазонфуроат монохидрат, метод за получаването му и фармацевтичен състав BG60755B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10

Publications (1)

Publication Number Publication Date
BG60755B2 true BG60755B2 (bg) 1996-02-29

Family

ID=24320279

Family Applications (1)

Application Number Title Priority Date Filing Date
BG098564A BG60755B2 (bg) 1990-09-10 1994-02-24 Мометазонфуроат монохидрат, метод за получаването му и фармацевтичен състав

Country Status (35)

Country Link
US (1) US6180781B1 (enExample)
EP (1) EP0548114B1 (enExample)
JP (1) JPH0725789B2 (enExample)
KR (1) KR960013445B1 (enExample)
CN (1) CN1030920C (enExample)
AT (1) ATE113604T1 (enExample)
AU (1) AU663471B2 (enExample)
BG (1) BG60755B2 (enExample)
CA (1) CA2091360C (enExample)
CZ (1) CZ281318B6 (enExample)
DE (2) DE19875032I2 (enExample)
DK (1) DK0548114T5 (enExample)
EE (1) EE02962B1 (enExample)
ES (1) ES2065701T3 (enExample)
FI (1) FI111078B (enExample)
HK (1) HK185996A (enExample)
HR (1) HRP920383B1 (enExample)
HU (1) HU213401B (enExample)
IE (1) IE67056B1 (enExample)
IL (1) IL99437A (enExample)
LU (1) LU90366I2 (enExample)
MX (2) MX9203396A (enExample)
MY (1) MY106644A (enExample)
NL (1) NL980012I2 (enExample)
NO (1) NO300548B1 (enExample)
NZ (1) NZ239711A (enExample)
OA (1) OA09772A (enExample)
PH (1) PH30443A (enExample)
PL (1) PL165803B1 (enExample)
PT (1) PT98905B (enExample)
SI (1) SI9111497A (enExample)
TW (2) TW229208B (enExample)
WO (1) WO1992004365A1 (enExample)
YU (1) YU48666B (enExample)
ZA (1) ZA917148B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0548114T5 (da) * 1990-09-10 1995-01-30 Schering Corp Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
EP1033991B1 (en) * 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
SI2124944T1 (sl) * 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
PT2435025T (pt) 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) * 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
DK0548114T5 (da) * 1990-09-10 1995-01-30 Schering Corp Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette

Also Published As

Publication number Publication date
FI931031L (fi) 1993-03-09
CZ281318B6 (cs) 1996-08-14
NZ239711A (en) 1992-09-25
ATE113604T1 (de) 1994-11-15
IL99437A0 (en) 1992-08-18
HU213401B (en) 1997-06-30
DE69104991D1 (de) 1994-12-08
NL980012I2 (nl) 2004-11-01
IE913155A1 (en) 1992-03-11
CN1030920C (zh) 1996-02-07
SI9111497A (sl) 1998-04-30
HUT64361A (en) 1993-12-28
FI111078B (fi) 2003-05-30
CA2091360C (en) 1997-04-08
OA09772A (en) 1993-11-30
EP0548114A1 (en) 1993-06-30
ES2065701T3 (es) 1995-02-16
FI931031A0 (fi) 1993-03-09
HRP920383B1 (en) 2000-04-30
KR960013445B1 (ko) 1996-10-05
NO300548B1 (no) 1997-06-16
MX9100990A (es) 1992-05-04
DE19875032I2 (de) 2007-04-19
ZA917148B (en) 1992-08-26
PT98905B (pt) 1998-08-31
MX9203396A (es) 1992-07-31
EP0548114B1 (en) 1994-11-02
YU48666B (sh) 1999-06-15
PH30443A (en) 1997-05-09
IL99437A (en) 1995-05-29
CA2091360A1 (en) 1992-03-11
HU9300685D0 (en) 1993-06-28
AU663471B2 (en) 1995-10-12
IE67056B1 (en) 1996-02-21
JPH05506667A (ja) 1993-09-30
CN1059911A (zh) 1992-04-01
NO930693D0 (no) 1993-02-26
PL165803B1 (pl) 1995-02-28
HRP920383A2 (en) 1998-06-30
TW272195B (enExample) 1996-03-11
YU149791A (sh) 1994-01-20
JPH0725789B2 (ja) 1995-03-22
WO1992004365A1 (en) 1992-03-19
HK185996A (en) 1996-10-11
AU8497491A (en) 1992-03-30
DE69104991T2 (de) 1995-04-20
DK0548114T5 (da) 1995-01-30
PT98905A (pt) 1992-09-30
TW229208B (enExample) 1994-09-01
US6180781B1 (en) 2001-01-30
LU90366I2 (fr) 1999-05-05
EE02962B1 (et) 1997-02-17
MY106644A (en) 1995-07-31
CZ38393A3 (en) 1994-01-19
NO930693L (no) 1993-02-26
NL980012I1 (nl) 1998-05-06

Similar Documents

Publication Publication Date Title
US6180781B1 (en) Process for making mometasone furoate monohydrate
US6127353A (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
EP3459933B1 (en) Solid forms of a pharmaceutically active compound
US9981985B2 (en) Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin SV and 3-formylrifamycin S and a process of their preparation
TWI672302B (zh) Bcl-2抑制劑之新結晶型、其製備方法及含其之醫藥組合物
JP3205816B2 (ja) 結晶性エトポシド４’−ホスフェートジエタノレート
WO2026086730A1 (zh) 恩美他唑巴坦的晶型及其制备方法
KR20100125124A (ko) 피타바스타틴 헤미칼슘염의 신규한 결정형 및 그의 제조방법
TW202313617A (zh) ＰＩ３Ｋδ抑制劑的鹽、其晶型、製備方法及用途
EP2880040A1 (en) Bortezomib esters and formulations thereof